Correction to: Lemborexant in insomnia disorder: a profile of its use

Hannah A. Blair¹

Published online: 1 October 2020
© Springer Nature Switzerland AG 2020

Corrections to:
Drugs & Therapy Perspectives (2020) 36:427–434
<https://doi.org/10.1007/s40267-020-00771-5>

The author has alerted us to the following errors, and the following corrections should be noted:

Page 431, ‘What is the tolerability profile of lemborexant?’ section, paragraph 2, lines 2–6: the following sentence, which previously read:

“Single and multiple doses of lemborexant 10 mg did not have any negative effects on the apnea-hypopnea index (a measure of OSA severity) or peripheral capillary oxygen saturation (a measure of respiratory function)”.

should read:

“Single and multiple doses of lemborexant 10 mg did not have any negative effects on the apnea-hypopnea index (a measure of OSA severity) or peripheral capillary oxygen saturation (a measure of respiratory function)”.

Page 433, reference list: Reference 12, which previously read:

12. Beuckmann CT, Ueno T, Nakagawa M, et al. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. *Sleep*. 2019;42(6).

should read:

12. Beuckmann CT, Ueno T, Nakagawa M, et al. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. *Sleep*. 2019;42(6):[zsz076](#).

Page 433, reference list: Reference 13, which previously read:

13. Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. *Sleep*. 2019;43(6).

should read:

13. Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. *Sleep*. 2019;43(6):[zsz302](#).

Page 434, reference list: Reference 16, which previously read:

16. Moline M, et al. Effect of lemborexant compared with placebo and zolpidem extended release on sleep architecture in older adults with insomnia disorder [abstract]. *Sleep Med*. 2019;64(Suppl 1):s437.

should read:

16. Moline M, [Pinner K](#), [Cheng J](#), et al. Effect of lemborexant compared with placebo and zolpidem extended release on sleep architecture in older adults with insomnia disorder [abstract]. *Sleep Med*. 2019;64(Suppl 1):s437.

Page 434, reference list: Reference 29, which previously read:

29. Vermeeren A, Jongen S, Murphy P, et al. On-the-road driving performance the morning after bedtime

The original article can be found online at <https://doi.org/10.1007/s40267-020-00771-5>.

✉ Hannah A. Blair
demail@springer.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand

administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019;42(4).

should read:

29. Vermeeren A, Jongen S, Murphy P, et al. On-the-road driving performance the morning after bedtime

administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019;42(4):[zsy260](#).

The original article has been updated.